Price: $0.0000
$0.00
%
|
Day's High:
| 0.00
| Week Perf:
|
|
Day's Low: |
$ 0.00 |
30 Day Perf: |
|
Volume (M): |
0 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
34 |
Employees |
2,400 |
Revenues (TTM) (Millions $) |
619 |
Net Income (TTM) (Millions $) |
37 |
Cash Flow (TTM) (Millions $) |
-15 |
Capital Exp. (TTM) (Millions $) |
65 |
Cambrex Corp
Cambrex Corporation is a global pharmaceutical contract development and manufacturing organization (CDMO) that specializes in the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) for the biopharmaceutical industry. The company was founded in 1981 and is headquartered in East Rutherford, New Jersey, United States.
Cambrex's services cover a wide range of areas, including custom development and manufacture of APIs, analytical development and testing, formulation development, and finished dosage form manufacturing. The company works with small to mid-sized biopharmaceutical companies, as well as multinational pharmaceutical corporations.
The company operates in three business segments: Small Molecules, Biologics, and Drug Product. The Small Molecules segment provides custom development and manufacturing services for APIs that are used in a variety of therapeutic areas, including oncology, anti-viral, anti-inflammatory, and cardiovascular. The Biologics segment specializes in the development and manufacture of biologic APIs, such as monoclonal antibodies, recombinant proteins, and vaccines. The Drug Product segment provides finished dosage form manufacturing, including capsule filling and tablet compression.
Cambrex has a strong global presence and operates a network of facilities in the United States, Europe, and Asia-Pacific. Its facilities are equipped with advanced technology and equipment, enabling the company to provide high-quality services to its customers. The company has a robust quality management system and is certified by regulatory agencies such as the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA).
The company has a strong track record of growth, driven by its focus on providing high-quality services to its customers. Cambrex has made strategic acquisitions, such as Halo Pharma in 2018, to expand its capabilities and strengthen its position in the CDMO industry. It has also made significant investments in research and development to develop innovative solutions for its customers.
In summary, Cambrex Corporation is a leading global CDMO that provides custom development and manufacturing services for APIs and finished dosage forms to the biopharmaceutical industry. With its strong global presence, advanced technology and equipment, and robust quality management system, Cambrex is well-positioned for further growth and success in the future.
Company Address: ONE MEADOWLANDS PLAZA EAST RUTHERFORD 7073 NEW JERSEY
Company Phone Number: 804-3000 Stock Exchange / Ticker: CBM
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Neurogene Inc
Neurogene Inc., a leading clinical-stage company specializing in genetic medicines for rare neurological disorders, has recently announced its plans to expand its Phase 1/2 gene therapy clinical trial for NGN-401. This trial is particularly focused on female pediatric patients suffering from Rett syndrome, a debilitating genetic disorder that primarily affects the nervous system. In addition to expanding the trial, Neurogene Inc. also aims to improve the enrollment process to allow for faster participation and assessment. Rett syndrome, although considered a rare condition, has a profound impact on the lives of patients and their families. It predominantly affects females and is caused by mutations in the MECP2 gene. Symptoms typically appear between six to eighteen months after birth and result in severe impairments in physical, cognitive, and social functioning. Children with Rett syndrome often lose purposeful hand skills, experience regression in language and motor abilities, exhibit repetitive hand movements, and develop respiratory irregularities. Currently, there is no cure for Rett syndrome, and treatment primarily focuses on managing symptoms and providing supportive care.
|
Eyenovia Inc
Eyenovia Inc, a major pharmaceutical preparations company, has witnessed a significant drop in its shares over the past month. This decline adds to the year-to-date poor performance. Additionally, the company is currently trading on the NASDAQ well below its 52-week average. These developments raise concerns about Eyenovia's future prospects and its ability to overcome these challenges. Furthermore, factors such as a co-promotion agreement and recent financial results also contribute to the uncertainty surrounding the company's future. 1. Co-Promotion Agreement with NovaBay Pharmaceuticals: Eyenovia's strategic partnership with NovaBay Pharmaceuticals aims to expand market presence and provide a wider range of ophthalmic solutions. Under this agreement, NovaBay will market Eyenovia's Clobetasol propionate ophthalmic suspension, while Eyenovia will promote NovaBay's Avenova Antimicrobial Lid and Lash Solution. This collaboration intends to effectively target eye care professionals across the United States. However, the impact and success of this agreement remain to be seen.
|
Avenue Therapeutics Inc
Avenue Therapeutics Inc, a prominent pharmaceutical company, has been making waves in the medical industry with its groundbreaking advancements in the treatment of various neurological disorders. Recently, the company presented its preclinical data on BAER-101 at the American Society for Experimental Neurotherapeutics Annual Meeting, showcasing its full suppression of seizure activity in absence epilepsy. This discovery has the potential to revolutionize anti-seizure drug development and significantly improve the lives of those affected by this condition. Absence epilepsy is a neurological disorder characterized by intermittent episodes of unconsciousness and staring spells. It predominantly affects children and adolescents, often leading to academic and social challenges. The underlying cause of this condition involves abnormal electrical activity in the brain, resulting in seizures characterized by momentary lapses in consciousness. Prompt and effective treatment is crucial in preventing long-term complications and enhancing the quality of life for individuals with absence epilepsy.
|
Leap Therapeutics Inc
Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million. Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.
|
Xbiotech Inc
Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects. One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.
|
Per Share |
Current |
Earnings (TTM) |
1.09 $ |
Revenues (TTM) |
18.26 $
|
Cash Flow (TTM) |
- |
Cash |
2.38 $
|
Book Value |
19.93 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
1.09 $
|
Revenues (TTM) |
18.26 $ |
Cash Flow (TTM) |
- |
Cash |
2.38 $
|
Book Value |
19.93 $ |
Dividend (TTM) |
0 $ |
|
|
|
|